Neural tube defects (NTDs) occur secondary to failed closure of the neural tube between the third and fourth weeks of gestation. The worldwide incidence ranges from 0.3 to 200 per 10,000 births with the United States of American NTD incidence at around 3-6.3 per 10,000 dependent on race and socioeconomic background. Human NTD incidence has fallen by 35-50% in North America due to mandatory folic acid fortification of enriched cereal grain products since 1998. The US Food and Drug Administration has approved the folic acid fortification of corn masa flour with the goal to further reduce the incidence of NTDs, especially among individuals who are Hispanic. However, the genetic mechanisms determining who will benefit most from folate enrichment of the diet remains unclear despite volumes of literature published on studies of association of genes with functions related to folate metabolism and risk of human NTDs. The advances in omics technologies provides hypothesis-free tools to interrogate every single gene within the genome of NTD affected individuals to discover pathogenic variants and methylation targets throughout the affected genome. By identifying genes with expression regulated by presence of folate through transcriptome profiling studies, the genetic mechanisms leading to human NTDs due to folate deficiency may begin to be more efficiently revealed.
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| INTRODUCTION
A neural tube defect (NTD) is a congenital malformation of the central nervous system (CNS) occurring secondary to failed closure of the neural tube between the third and fourth weeks of gestation. NTDs affect approximately 300,000 live births worldwide every year and the incidence in different areas ranges from 0.03 to 20 per 1,000 births (Zaganjor et al., 2016) . The most common types of human NTDs occurring in approximately equal frequencies at birth are: spina bifida (SB) with lack of closure in the spinal cord region and anencephaly with lack of closure in the cranial region (Botto, Moore, Khoury, & Erickson, 1999; Melvin et al., 2000) . Individuals with anencephaly usually die within days of birth. Advances in medical care and surgical procedures have greatly improved the survival of the majority of individuals affected by SB. SB is a broad term that includes myelomeningocele (MM), meningocele, and lipomeningocele. The most common SB is MM (protrusion of the nervous tissue and its covering through a defect in the vertebrae) accounting for more than 90% of SB cases. In this review, the terms NTD and SB will be used throughout; however, most of the human genetic studies reviewed are primarily focused on MM.
For the epidemiological studies that are discussed, NTD refers to all reported human NTDs, including anencephaly and SB.
Current NTD incidence in the United States (US) is around 3-6.3 per 10,000 live births annually dependent on race, geographic locations, socioeconomic background, and birth defects surveillance information available from each state (Parker et al., 2010; Zaganjor et al., 2016) . The estimated hospital care costs for a child born with SB range between $21,900 and $1,350,700 in the first year of life (Radcliff et al., 2012) . Intriguingly, the incidence of human NTDs fell by 35-50% in North America due to mandatory folic acid (FA) fortification of enriched cereal grain products in 1998 providing some relief to the large public health burden (CDC, 2009; Grosse, Berry, Mick Tilford, Kucik, & Waitzman, 2016; Noami, Bernstein, Boucher, Rieder, & Parker, 2016; Williams et al., 2015) . However, NTD incidence in Hispanic Americans remains the highest among all races in the US. This population is the least likely to benefit from wheat flour fortification due to a preference for a corn masa flour-based diet (Hamner et al., 2013) . On April 15, 2016, the USFDA approved the FA fortification of corn masa flour to help increase FA intake for Hispanic American women of childbearing age with the goal of reducing the incidence of NTDs (DHHS FDA 21 CFR Part 172, 2016) .
Despite reports from various parts of the world demonstrating reproducible results of the benefits of FA in reducing NTD occurrence and recurrence in the past two decades, the underlying molecular mechanisms remain unknown. There continues to be an estimated 30% of NTD cases that do not respond to FA supplementation (Crider, Bailey, & Berry, 2011) . In the past 25 years after the first discovery that NTD risk can be reduced with increased maternal folate uptake, there were extensive animal and human studies undertaken to facilitate our understanding of the genetics of NTDs. However, these studies have only enabled scientists to examine a limited number of genetic and epigenetic factors with minimal success in demonstrating association or pin-pointing molecular mechanism(s) on how folate one-carbon metabolism genes contribute to NTD risks in humans. Undoubtedly, in the "Omics" era, many exciting new tools including next generation sequencing will allow us to conduct hypothesis-free studies making it possible to interrogate every human gene to search for risk factors influenced by folate deficiency in NTD cases. Identifying specific genetic and epigenetic factors leading to human NTDs can enable health care providers to design knowledge-based gene-nutrition supplementation plans that may minimize NTD pregnancy risk. This review will summarize the genetics studies of human NTDs to provide a snapshot of our current understanding of the biological mechanisms of folate to NTD development, specifically SB.
| ENVIRONMENTAL FACTORS AND EPIGENETICS OF HUMAN NTDs
Expression of genes can be influenced by methylation of DNA, small RNAs and proteins. A review showed support that a wide variety of environmental factors (e.g., chemical pollutants, diets, temperature changes, and external stresses) can contribute to long-lasting effects on establishment and maintenance of epigenetic modifications that could thereby influence gene expression and phenotype (Feil & Fraga, 2012; Price, Peñaherrera, et al., 2016; Yue, Liu, & He, 2015) . A study of the methylomes in lymphocytes of human SB subjects showed significant overall hypomethylation of SOX18, a gene not known to associate with NTDs (Rochtus et al., 2016) . This study also showed that addition of sox18 mRNA by injection into zebrafish embryos led to abnormal neural tube closure (Rochtus et al., 2016) . In addition, abnormal microRNA profiles were observed in human anencephaly brain tissue suggesting activity of microRNAs can be modified through post-transcriptional methylation (Berulava, Rahmann, Rademacher, Klein-Hitpass, & Horsthemke, 2015) . Many non-genetic/environmental factors in addition to folate have been demonstrated to contribute to NTD risk in numerous epidemiologic studies. For the past three decades, studies have investigated contributing risk factors including socioeconomic status; parental education (Brough, Rees, Crawford, & Dorman, 2009; Canfield et al., 2009; Grewal, Carmichael, Song, & Shaw, 2008) ; maternal and paternal ages (Vieira & Castillo Taucher, 2005) ; parental occupations (Brender, Felkner, Suarez, Canfield, & Henry, 2010; Fear, Hey, Vincent, & Murphy, 2007; Herdt-Losavio et al., 2010; Shaw, Nelson, & Olshan, 2002; Yang, Carmichael, Canfield, Song, & Shaw, 2008) ; maternal reproductive history including maternal country of birth and country of conception (Canfield et al., 2009) ; hyperthermia during early pregnancy (Feldkamp, Meyer, Krikov, & Botto, 2010; Moretti, Bar-Oz, Fried, & Koren, 2005) ; glucose intolerance/diabetes or obesity ; maternal intake of caffeine (Schmidt et al., 2009 ); maternal medications (Alwan, Reefhuis, Rasmussen, Olney, & Friedman, 2007; Crider et al., 2009; Matok et al., 2009) ; and toxic heavy metal exposure during early pregnancy (Mazumdar et al., 2015) .
The non-genetic factors discussed above play some direct and indirect roles influencing the maternal and fetal epigenomes and increasing the risk of failed neural tube closure although the underlying molecular mechanisms are mostly unknown. Epigenetic factors may also vary with the genetic variations present in affected individuals, thereby influencing NTD risk (Greene, Stanier, & Moore, 2011; Price, Peñaherrera, et al., 2016) .
| GENETIC ETIOLOGY OF HUMAN NTDs
Genetic risk factors are important in NTD formation. First, individuals of Irish or Mexican descent have an a priori risk for NTDs which is higher than that of individuals of other Caucasian or of Asian descent (CDC, 2009; Njamnshi et al., 2008; Ray, Vermeulen, Meier, Cole, & Wyatt, 2004) . Second, siblings of an NTD patient have a 3% or higher risk of having NTD, a 30 times increase over the population NTD risk of 0.1%, and offspring of second degree relatives has an increased risk of 0.5% (Toriello & Higgins, 1983) . Third, more than 200 mouse models of NTD, naturally occurring and genetically engineered, have been identified (Harris, 2009; Harris & Juriloff, 2007 , 2010 . Fourth, about 1/5 of individuals with craniorachischisis were found to have deleterious variants in genes regulating planar cell polarity (Harris & Juriloff, 2010) . Finally, a number of human syndromes have NTDs as a phenotypic feature suggesting genetic etiologies.
To date, over 300 studies attempting to find association of selected genes with human NTDs have been published. These studies, AU ET AL.
| 3043 almost exclusively of simplex patients and their unaffected parents, have examined over 150 polymorphic variants in candidate genes with known functions involving various aspects of biological activity (Boyles, Hammock, & Speer, 2005; Greene, Stanier, & Copp, 2009 ).
The majority of the human association studies, both case-control and family-based, consist of MM cases together with other types of NTDs.
Conventional genomewide linkage studies have rarely been undertaken because large, multigenerational families including multiple members affected with NTDs are uncommon. Genomewide association study (GWAS) has not been possible because human NTDs represent a rare complex trait precluding accumulation of a sufficiently large sample size in the thousands to achieve the statistical power necessary to detect an elevation of risk between 1 and 2. In addition, the statistical power for GWAS is further reduced with the diverse confounding factors present among patient populations with NTDs.
Many recent studies have implicated rare genetic variants as contributing major effects in common complex diseases (Cirulli & Goldstein, 2010) . Indeed, approaches used to scan through sequences of candidate genes in exomes of affected subjects have identified rare deleterious genetic variants potentially contributing to some human NTDs (Connealy, Northrup, & Au, 2014; De Marco et al., 2014; Lemay et al., 2015; Ruggiero, Northrup, & Au, 2015; Wang, De Marco, et al., 2015) . The impact of the FA fortification mandate on the penetrance of variants in genes rescuable by FA should be carefully weighed when designing studies to identify these variants. Enrolling study subjects, cases, and controls, born before FA fortification period is necessary because controls without NTDs may include individuals with NTDs rescued by FA from food intake.
An alternative candidate gene association study approach based on findings from mutant NTD mouse models has produced interesting results in some cases (Harris & Juriloff, 2007 
| REVIEW METHODOLOGY
Peer-reviewed articles are extracted from the PubMed/Medline. A list of genes coding for transporters and carriers of essential biomolecules for FOCM network were compiled from NCBI-Gene (https://www. ncbi.nlm.nih.gov/gene/) using the term of the specific biomolecule with "transporter" and/or "carrier" ( Table 1 ). The FOCM network genes have been identified and described in the scientific literature and metabolic pathway studies providing the overall information to compile a list of genes as shown in Tables 2-6 (Damaraju, Cass, & Sawyer, 2008; Fox & Stover, 2008; Litwack, 2008) . For this review, we Guo et al. (2013) , Jensen et al. (2004) , Kim (2016) , Marini et al. (2011 ), O'Byrne et al. (2010 , O'leary et al. (2006) , Pei, Liu, Zhang, Zhu, and Ren, (2009), Relton, Wilding, Laffling, et al. (2004) , Relton, Wilding, Pearce, et al. (2004) , Shang et al. (2008) , Shaw et al. (2009) searched for articles indexed in Pubmed/Medline using the term "human neural tube defects" and the name of each gene from the compiled list. Together, 30 FOCM network genes, 47 FOCM biomolecules transporting genes, 4 glycine cleavage system genes, and 15 transsulfuration genes were searched for association with human neural tube defects studies. We used "methyltransferase"
and "human neural tube defects" terms to identify articles reporting human NTD association studies on any methyltransferase (MTase) genes. This review aims to report which FOCM network genes have or have not been studied for association with human NTDs. Original 
| Transport/retention of necessary biomolecules and human NTDs
The FOCM cycle and the interlocking network of cycles involve many biomolecules that depend on transporters and carriers for cell uptake and enzymes to modify biomolecules for cell retention to sustain intracellular supply ( (Damaraju et al., 2008) .
Only a promoter polymorphism of ABCC2 was tested for association with spina bifida risk in humans (Jensen et al., 2004) . Interestingly, a recent study has demonstrated that LDL receptor 2 (Lrp2) is essential for mediating folate uptake and folate deficiency in the Lrp2 knockout Methionine is an essential amino acid for humans, and it has been suggested to be protective for NTD risk in one association study (Graham et al., 2010) . Methionine from diet can be transported efficiently via amino acid carriers (e.g., SLC43A2, SLC7A5) into cellular compartments and is vital for synthesis of all proteins and to maintain the Met cycle. Mouse embryos with Slc7a5 knocked out died with failure of the anterior neural tube to close and a cruciform caudal neural tube (Poncet, Shi, Taylor, & Storey, 2014 ), but it is not known whether the human homolog SLC7A5 contributes to risk of NTD in humans.
Glycine and serine are two important biomolecules for the FOCM and Met/Hcy cycles and are transported into cells via several amino acid transporters (e.g., SLC32A1, SLC6A9, and SLC6A5 for glycine; SLC1A4, SLC3A2, and SLC7A10 for serine). Pyridoxal-5-phosphate is an active coenzyme for cystathionine-β-synthase (CBS) and converts homocysteine (Hcy) and serine into cystathionine for cysteine synthesis. Pyridoxal-5-phosphate is converted from vitamin B6
(pyridoxine) by intracellular pyridoxal kinase (PDXK) and pyridoxamine 5′-phosphate oxidase (PNPO).
The active form of cobalamin (vitamin B12), CH3-B12, is a required coenzyme for MTR to convert Hcy and mTHF to THF and Met. B12 from the diet will be transported into cells by cubulin (CUBN) and transcobalamins (e.g., TCN1, TCN2, and CD320). Alternatively, oxidized B12 is converted to CH3-B12 by MTRR to re-activate MTR activity. Alternatively, Hcy can be converted into Met by BHMT with betaine as a co-enzyme, and betaine can be transported into cells by different transporters (e.g., SLC6A18, SLC38A2, and SLC6A12). In addition, betaine can be converted from choline by CHDH and ALDH7A1 in mitochondria. Dietary choline can be transported into cells by several transporters (e.g., SLC5A7, SLC44A1, and SLC44A2) to synthesize betaine.
Only a small number of biomolecule transporters/carriers for folate and vitamin B12 (e.g., CUBN, TCN2, FOLH1, FOLR1-3, and SLC19A1) have been examined for association with NTD risk in humans (Franke et al., 2009; Godbole et al., 2011; O'Byrne et al., 2010; Pangilinan et al., 2012 carrier genes of necessary biomolecules should be examined for deleterious variants to determine whether they may contribute to human NTDs. Therefore, expanding the search for association of the FOCM biomolecules transporters and human NTDs risks may be warranted.
| Folate one-carbon metabolism genes and human NTDs
All of the genes in the folate metabolism cycle in the cytoplasm, mitochondria, and nucleus are obvious candidates for risk association studies of folate-responsive NTDs (Beaudin & Stover, 2009) . DHFR, MTHFR, MTHFD1, MTR, MTRR, and TYMS are among the most studied genes, and their mitochondrial counterparts are also gaining attention (Table 2 ). The most extensively studied is the MTHFR gene with over 100 published articles including a wide spectrum of populations (Boyles et al., 2005; Greene et al., 2009) explaining why the CH3THF producing enzyme MTHFR continuously attracts large interest in human NTD association studies (Leung et al., 2013 with MTHFR deficiency as a disease mechanism (Tsang et al., 2015) .
Our group has identified an MTHFR promoter SNP (rs3737965) that is associated with SB risk using family-based reconstruction combined transmsission disequilibrium test (RC-TDT) (Martinez et al., 2009) . A recent GWAS with a large sample size (4,763 women in the USA) found rs3737965 associated with lower plasma folate levels, but not elevated plasma Hcy levels (Hazra et al., 2009 ). The result for rs3737965 was a more significant p-value than that observed for c. human NTDs risk remains inconclusive (Etheredge et al., 2012; Pangilinan et al., 2012; Piao et al., 2016; Shaw et al., 2009; Wilding et al., 2004) . New and known nonsynonymous variants were identified in GART and ATIC in patients with NTDs and were suggested to be associated with NTD risk in Hispanic subjects (Marini et al., 2011) . In addition to GART, ATIC, and TYMS, there are many other genes coding for enzymes in purine and pyrimidine biosynthesis. Whether or not other genes coding for enzymes participating in nucleobase biosynthesis can influence NTD risk in humans is largely unknown. 
| Methionine cycle genes and human NTDs

| Glycine cleavage system genes and human NTDs
The glycine cleavage system (GCS), part of the glycine and serine catabolism pathway, plays an important role in mitochondrial FOCM.
GCS is composed of four enzymes: glycine dehydrogenase (GLDC), aminomethyltransferase (AMT), glycine cleavage system protein H (GCSH), and dihydrolipoamide dehydrogenase (DLD). These four enzymes attach to the inner membrane of the mitochondria in response to high concentrations of glycine (Kikuchi, 1973) . Bi-allelic pathogenic variants of genes in GCS lead to the development of nonketotic hyperglycinemia (NKH, OMIM #605899). NKH is an autosomal recessive inborn error of metabolism which causes accumulation of glycine and results in encephalopathy and often death (Azize et al., 2014; Kure et al., 2006) . Biallelic pathogenic variants in DLD have not been described among patients with NKH, and instead causes dihydrolipoamide dehydrogenase deficiency (DLDD OMIM #246900) (Narisawa et al., 2012) . Mouse embryos with
Amt knocked out develop NTDs with undetectable activity of GCS demonstrating AMT function is essential for GCS activity and successful neural tube closure. A link between NKH and NTDs was similarly established after a mouse model with Gldc knocked out also develop NTDs (Pai et al., 2015) .
In a more recent study to identify the genetic etiology of subjects affected by MM, our group identified six novel heterozygous variants in the AMT gene and three of them (p.Val7Leu, p.Pro251Arg, and p.Val380Met) are predicted to be deleterious to AMT function (Shah, Northrup, Hixson, Morrison, & Au, 2016) . In addition, five extremely rare known heterozygous variants were found in the AMT gene and one in the GLDC gene providing additional support that genetic variations in the GCS genes may contribute to the risk of human NTDs.
No novel variants in the exons of the other two GCS genes DLD and GCSH were identified. Consistent with previous findings, deleterious variants in GCS genes in offspring play a small role in increasing NTD risk. As discussed above, the role of glycine and serine transporters should not be ignored since both amino acids can be derived from diet and transported into cells by their corresponding transporters.
| Methylation and human NTD association
S-Adenosyl methionine (SAM), an intermediate biomolecule in the
Met/Hcy cycle, is a major methyl group donor in transmethylation of a large spectrum of biomolecules (nucleic acids, proteins, phospholipids, amino acids, neurotransmitters, and many other toxic compounds).
Sequencing data from the Human Genome Projects has led to FIGURE 1 Folate one-carbon metabolism and interacting pathways components. Folate one-carbon metabolism (FOCM) and methionine cycle (Met cycle) is a major metabolic pathway involving many biomolecules involved in multiple metabolic pathways vital to cell survival, cell growth, and proliferation, and cell differentiation. The participating biomolecules include different forms of folates, B-vitamins, betaine, choline, serine, glycine, threonine, and methionine for FOCM/Met metabolism, and glucose to genearate energy for the metabolic processes. Biomolecules breaking down from food by maternal digestive enzymes will be absorbed by maternal enterocytes. Absorbed biomolecules will be transported into maternal circulation to supply maternal cells and organs and also to the developing embryo via the placenta during pregnancy. FOCM biomolecules transported into cells will be utilized by the FOCM/Met cycle enzymes producing important substrates for the downstream network of metabolic pathways including purine and pyrimidine synthesis, glycine cleavage, NADPH/NADP synthesis, peroxides transsulfuration, protein synthesis, phospholipid synthesis, and transmethylation of DNA, RNA, and protein. Ser, serine; Gly, glycine; Thr, threonine; Met, methionine; Hcy, homocysteine; SAM, S-adenosyl-methionine; THF, tetrahydrofolate; fTHF, formyl-THF; CH2THF, methylene-THF; CH3THF, methyl-THF. B-vitamins: B2, riboflavin; B6, pyridoxine; B9, folic acid or THF; B12, cobalamins; PE, phosphatidylethanolamine; PS, phosphatidylserine; PC, phosphatidylcholine discovery of hundreds of human genes that contain coding domains similar to the characterized MTases and catalogued by the Human Genome Organization (HUGO) Gene Nomenclature Committee HGNC (Table 5, ebi.ac.uk/interpro/entry/IPR029063) (Martin & McMillan, 2002; Mitchell et al., 2014; Schubert, Blumenthal, & Cheng, 2003; Wlodarski et al., 2011) . Variation in function of various MTases that play important roles in growth, differentiation, and proliferation of cells may also be risk factors for susceptibility to NTD formation under folate deficient conditions (Blom, 2009; Crider et al., 2011; Imbard, Benoist, & Blom, 2013) . Many genes involved in transmethylation of nucleic acids (e.g., AMD1, ATIC, DNMT1, DNMT3A, GAMT, GART, MGMT, RNMT, and TRDMT1), proteins/amino acids (e.g., ICMT, PCMT1, PRMT1, and PRMT2), coenzymes and drug metabolism (e.g., COQ3, NAT1, NAT2, and NNMT), and lipids (e.g., CHKA, MUT, PCYT1A, and PEMT) have been examined for their potential contribution to risk of human NTDs, but the results were mixed (Boyles et al., 2005; Franke et al., 2009; Greene et al., 2009) . In a study of methylated DNAs from second trimester human placental tissues of NTD-affected patients and controls in Canada, differentially methylated array sites were identified between patients with SB and control individuals in the kidney, suggesting a common etiology for abnormal neural tube and renal development (n = 3342 sites) (Price, Lillycrop, & Burdge, 2016) . A review of the nutritional, biological, and genetic risk factors for NTDs in human and animal models led to a conclusion that folate and defects in the enzymes in FOCM individually are not sufficient to cause NTDs (Imbard et al., 2013) . Other components such as metabolism of choline, betaine, and B12 (which is essential for optimal methylation) and transmethylation are emerging as potential risk factors (Imbard et al., 2013) . With next-generation sequencing Omics tools, an in-depth evaluation of all MTase genes for association with human NTDs will
shed light on what role MTases play in human NTD risk.
| Methyltransferases for nucleic acids and human NTDs
DNA MTases (DNMTs) methylate DNA at the 5′-position of cytosine as the predominant epigenetic modification process in mammals.
Methylation error can play a causal role in a variety of diseases, including cancer and NTDs (Robertson, 2001; Rochtus, Jansen, Van Geet, & Freson, 2015) . In a chicken neural tube closure study, DNMT3A played a role in switching off neural tube transcription factor genes facilitating neural crest gene expression (Hu, Strobl-Mazzulla, Sauka-Spengler, & Bronner, 2012) . It has been suggested that methylation of genomic DNA is associated with risk of SB in China (Shangguan et al., 2015) . SNPs in DNMT3A have been demonstrated to be associated with NTD risk in humans with nominal significance (Pangilinan et al., 2012) . Mice with null Dnmt3b developed rostral neural tube abnormalities but DNMT3B has not been associated with human NTDs (Okano, Bell, Haber, & Li, 1999) . No association with human SB was found with other methyltransferases (i.e., AMD1, ATIC, DNMT1, GAMT, GART, and MGMT) targeting DNA (Franke et al., 2009 ).
Most recently, epitranscriptome studies have revealed modifications of RNAs by methylation (e.g., N6-methyladenosine or m6A, 5-methylcytosine or m5C, and pseudo-uridine) at different locations.
Regulation and function of these dynamic mRNA marks can determine splicing, nuclear export, capping, re-coding, translation efficiency, and stability (Gilbert, Bell, & Schaening, 2016; Popis, Blanco, & Frye, 2016; Yue et al., 2015) The dynamic changes of the mRNA marks can affect cell fates, development, and disease (Klungland & Dahl, 2014; Wang, 2016 (Arrowsmith, Bountra, Fish, Lee, & Schapira, 2012; Huang & Berger, 2008; Kouzarides, 2007 (Wang et al., 2013; Zhao et al., 2012; Zhu et al., 2006) . No association for ICMT, MGMT, PRMT1, and PRMT2 with SB risk was observed (Franke et al., 2009 ).
However, the role of all other MTases in risk of human NTDs has not been fully examined.
| Methyltransferases for lipids and human NTDs
In the PEMT pathway, SAM donates a methyl group to phospholipid phosphatidyl-ethanolamine (PE) to make phosphatidyl-choline (PC).
PC and PE are main components of cellular membrane structures forming cellular organelles and cell-cell barriers. Metabolites from choline and phosphatidylcholine synthesis and degradation may AU ET AL.
influence cell cycle regulation and cell fate (Ridgway, 2013) . In addition, oxidation of choline produces betaine, a methyl donor of Hcy to synthesize methionine. A study found increasing intake of methionine may have a protective effect against NTDs (Graham et al., 2010) . Increased maternal intake of dietary choline has been suggested to reduce risk of NTDs. Mouse embryos exposed to choline uptake inhibitors developed NTDs (Fisher, Zeisel, Mar, & Sadler, 2001; Lavery et al., 2014; Shaw, Carmichael, Yang, Selvin, & Schaffer, 2004) .
Choline kinase A (CHKA) and lack of choline intake have been shown to be associated with risk for human SB (Enaw et al., 2006) . A study by Pangilinan et al. (2012) showed PEMT was associated with NTD in the Irish population, but no association was found in patients in the USA . It is not clear whether genes coding for enzymes in the PEMT pathway or choline and betaine metabolism contribute to risk of human NTDs.
| Other methyltransferases and human NTDs
Some studies have suggested environmental toxic chemicals such as arsenic compounds can lead to NTDs in animal model but the genetic mechanism is largely unknown (Chaineau, Binet, Pol, Chatellier, & Meininger, 1990; Ferm & Carpenter, 1968; Wlodarczyk, Bennett, Calvin, & Finnell, 1996) . So far, the association of toxic chemicals such as pesticides, mercury, lead, cadmium, and arsenic with risk of NTDs in humans remains inconclusive (Brender et al., 2006; Jin et al., 2013) .
Interestingly, a recent study with a small sample size has demonstrated that AS3MT and DNMT3A (MTases for arsenate and DNA, respectively) were associated with NTD risk in women with high plasma arsenates (Mazumdar et al., 2015) . Another study for ubiquinone, guanidoacetate, and nicotinamide methyltransferases (i.e., COQ3, GAMT, and NNMT) failed to demonstrate association with human SB risk (Franke et al., 2009) . Overall, the role of MTase function in detoxifying drugs and toxic heavy metals and human NTD risk has not been fully investigated.
5.8 | Transsulfuration/reactive oxygen species reduction genes and human NTDs Only two genes (CBS and CTH) in this pathway have been tested for association with NTD risk (Table 6 ). The c.844ins68bp and SNP c.833T>C (rs5743905) of the CBS gene that potentially code for a truncated form of CBS have been studied by many groups on different patient groups with numbers ranging from 40 to 200 (Greene et al., 2009; Martinez et al., 2009 were associated with human NTDs only in some ethnic populations and appear to be in conflict with the overall effect that increased folate uptake reduces NTD incidence throughout the world.
Inconsistent results reported between the case-control and the family-based studies are possibly secondary to sample variability, variable phenotypes, and small sample sizes. These conflicting results may be resolved with additional replication studies adjusted for confounding factors. There is insufficient evidence suggesting that the most commonly tested genetic variations leading to defects in the enzymes in the FOCM/Met cycles are the major molecular mechanisms contributing to rescue of the majority of human NTDs cases by folate supplementation. In fact, studies have shown that FA can alter expression of genes mediating cell growth, proliferation, and apoptosis, and these genes have not been shown to respond to FA availability (Price, Lillycrop, & Burdge, 2016) . The practice of FA fortification in food crops in the US has led to more than 35% reduction in NTD prevalence and effectively rescued a significant portion of individuals from having NTDs who carry deleterious FOCM network genes variants. As a result, the penetrance of deleterious variants in the FOCM network gene among subjects with
NTDs after 1998 is expected to shift. Therefore, cautions must be taken to only select study subjects and controls born before 1998 in order to examine the role of FOCM network genes as risk factors for human NTDs.
Results of genetic association studies using common SNPs have been mixed. There is increasing evidence supporting a role for rare/novel/de novo variant in NTDs (Au, Ashley-Koch, & Northrup, 2010) . Recent studies have suggested that while contribution of these variants in the PCP pathway genes contributed to more than 20% of severe human NTDs that involve the head (e.g., craniorachischisis), variants in these genes provided minimal contribution to the occurrence of spina bifida (Juriloff & Harris, 2012) . We have observed similar association for rare variants in several FOCM genes in a select group of MM subjects, and gene-disrupting de novo copy number variations (CNVs) might contribute to less than 8% of the etiology in MM subjects (Bassuk et al., 2013) Only with a knowledge-based evaluation of the involved specific genetic and epigenetic factors, will medical care providers be able to identify women of childbearing age who are mostly likely to benefit from folate supplementation to minimize risk of NTDaffected pregnancies. Concurrently, researchers can begin exploring other non-genetic factors as alternatives for the woman least likely to be responsive to folate supplementation to reduce risk of NTD-affected pregnancies.
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